Gryphon Financial Partners’s Argos Therapeutics, Inc. ARGS Stock Holding History

Gryphon Financial Partners’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50	Closed	–	–	1040
2018 Q1	$0	Hold	50	–	–	﹤0.01%	1076
2017 Q4	$0	Buy	+50	New	+$168	﹤0.01%	1039

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Gryphon Financial Partners's ARGS Position: Q2 2018 in Review

Gryphon Financial Partners sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 50 shares.

Gryphon Financial Partners first reported a position in ARGS in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

Gryphon Financial Partners reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Gryphon Financial Partners sold 50 Argos Therapeutics, Inc. shares in Q2 2018.
Gryphon Financial Partners first reported a position in Argos Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
Gryphon Financial Partners's Argos Therapeutics, Inc. position peaked at $0 in Q1 2018.
4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Gryphon Financial Partners's 13F filing for Q2 2018, filed 14 Aug 2018.